A Fatal Case of Immune Checkpoint Inhibitor-Associated Myocarditis with Severe Right Ventricular Failure.

IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
International heart journal Pub Date : 2025-05-31 Epub Date: 2025-05-15 DOI:10.1536/ihj.24-701
Takuro Imaoka, Kimi Sato, Shingo Sakashita, Yuma Shibutani, Atsuko Suzuki, Daisuke Kotani, Kohei Shitara, Kazuko Tajiri
{"title":"A Fatal Case of Immune Checkpoint Inhibitor-Associated Myocarditis with Severe Right Ventricular Failure.","authors":"Takuro Imaoka, Kimi Sato, Shingo Sakashita, Yuma Shibutani, Atsuko Suzuki, Daisuke Kotani, Kohei Shitara, Kazuko Tajiri","doi":"10.1536/ihj.24-701","DOIUrl":null,"url":null,"abstract":"<p><p>A 70-year-old man with esophageal cancer undergoing nivolumab treatment presented to our hospital with suspected myocarditis associated with immune checkpoint inhibitor (ICI) therapy. The initial echocardiographic assessment upon admission demonstrated a preserved left ventricular (LV) ejection fraction but impaired right ventricular (RV) function. An endomyocardial biopsy revealed significant lymphocytic infiltration and myocyte necrosis. High-dose steroid therapy was initiated on the day of admission. However, on the following day, RV function deteriorated further, and LV dysfunction emerged, resulting in hemodynamic collapse and necessitating mechanical circulatory support. Despite additional immunoglobulin therapy, cardiac function failed to improve, and the patient died 9 days after admission. This case underscores the critical need for vigilant monitoring of both LV and RV function in patients undergoing ICI therapy to detect and manage potential cardiovascular complications promptly.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"511-515"},"PeriodicalIF":1.2000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International heart journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1536/ihj.24-701","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

A 70-year-old man with esophageal cancer undergoing nivolumab treatment presented to our hospital with suspected myocarditis associated with immune checkpoint inhibitor (ICI) therapy. The initial echocardiographic assessment upon admission demonstrated a preserved left ventricular (LV) ejection fraction but impaired right ventricular (RV) function. An endomyocardial biopsy revealed significant lymphocytic infiltration and myocyte necrosis. High-dose steroid therapy was initiated on the day of admission. However, on the following day, RV function deteriorated further, and LV dysfunction emerged, resulting in hemodynamic collapse and necessitating mechanical circulatory support. Despite additional immunoglobulin therapy, cardiac function failed to improve, and the patient died 9 days after admission. This case underscores the critical need for vigilant monitoring of both LV and RV function in patients undergoing ICI therapy to detect and manage potential cardiovascular complications promptly.

免疫检查点抑制剂相关性心肌炎合并严重右心室衰竭1例死亡
一名70岁食管癌患者接受纳沃单抗治疗,疑似心肌炎伴免疫检查点抑制剂(ICI)治疗。入院时最初的超声心动图评估显示左心室(LV)射血分数保留,但右心室(RV)功能受损。心内膜活检显示明显的淋巴细胞浸润和心肌细胞坏死。入院当天开始大剂量类固醇治疗。然而,第二天,左室功能进一步恶化,出现左室功能障碍,导致血流动力学塌陷,需要机械循环支持。尽管进行了额外的免疫球蛋白治疗,心功能仍未改善,患者在入院后9天死亡。本病例强调了在接受ICI治疗的患者中警惕监测左室和右室功能的重要性,以及时发现和处理潜在的心血管并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International heart journal
International heart journal 医学-心血管系统
CiteScore
2.50
自引率
6.70%
发文量
148
审稿时长
6-12 weeks
期刊介绍: Authors of research articles should disclose at the time of submission any financial arrangement they may have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product. Such information will be held in confidence while the paper is under review and will not influence the editorial decision, but if the article is accepted for publication, the editors will usually discuss with the authors the manner in which such information is to be communicated to the reader.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信